Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003833 · ClinicalTrials.gov registry record
Genetic Study in Patients With Stage II or Stage III Colon Cancer
A clinical trial of Colorectal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- 598
- Enrollment target
- 20
- Study locations
NCT00003833: Completed study of Colorectal Cancer, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003833 is a study of Colorectal Cancer that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 598 participants, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003833, a study of Colorectal Cancer, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- 598 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer. PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.
Conditions Studied
Interventions
- GENETIC DNA stability analysis
- GENETIC gene mapping
Study Locations (20)
British Columbia
- Nanaimo Cancer Clinic - Nanaimo
- British Columbia Cancer Agency - Fraser Valley Cancer Centre - Surrey
- Prostate Centre at Vancouver General Hospital - Vancouver
- British Columbia Cancer Agency - Vancouver
- St. Paul's Hospital - Vancouver - Vancouver
- G. Steinhoff Clinical Research - Victoria
Ontario
- Royal Victoria Hospital, Barrie - Barrie
- William Osler Health Centre - Brampton
- Northeastern Ontario Regional Cancer Centre, Sudbury - Greater Sudbury
- Hamilton and District Urology Association - Hamilton
- London Health Sciences Centre - London
New Brunswick
- Moncton Hospital - Moncton
- Doctor Leon Richard Oncology Centre - Moncton
- Saint John Regional Hospital - Saint John
Alberta
- Tom Baker Cancer Center - Calgary - Calgary
- Lethbridge Cancer Clinic - Lethbridge
Nova Scotia
- Nova Scotia Cancer Centre - Halifax
- Cape Breton Cancer Centre - Sydney
Minnesota
- St. Mary's/Duluth Clinic Health System - Duluth
Newfoundland and Labrador
- Newfoundland Cancer Treatment and Research Foundation - St. John's
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 598 participants |
| Start Date | 1999-02 |
| Est. Completion | 2006-08 |
What the finished NCT00003833 record still lists
NCT00003833 is an observational study that tracks outcomes without assigning an intervention. The registered 598 participants enrollment target is mid-sized for trials with a published cap, below the 1,543-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (61% lower).
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which DNA stability analysis is the first listed.
NCT00003833 names 20 study sites across 7 states, led by British Columbia, Ontario, New Brunswick.
Frequently Asked Questions
What is clinical trial NCT00003833 about?
NCT00003833 is a clinical study titled "Genetic Study in Patients With Stage II or Stage III Colon Cancer". RATIONALE: Genetic studies may help in understanding the genetic processes that cause some types of cancer. PURPOSE: Genetic trial to study certain genes of patients who have stage II or stage III colon cancer.
What is the current status of trial NCT00003833?
This trial is currently completed. The enrollment target is 598 participants. The study started on 1999-02. Estimated completion is 2006-08.
What conditions does trial NCT00003833 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT00003833?
The interventions under investigation include: DNA stability analysis (GENETIC), gene mapping (GENETIC).
Who is sponsoring clinical trial NCT00003833?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003833 being conducted?
This trial has 20 study locations across Minnesota, Alberta, British Columbia, New Brunswick, Newfoundland and Labrador. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003833's enrollment target sits among peer trials
598 74th of 381 higher than 308 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06875973 · 599 participants · Phase 3
Pelacarsen Roll-over Extension Program
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia